The prolonged fast.
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
For patients suspected of hyperinsulinism (1), whose spells eluded blood glucose documentation, provocation of symptomatic hypoglycemia by food deprivation became de rigueur once insulinoma had been identified at the Mayo Clinic in 1927 (2) as the cause of this condition. The duration of fasting varied from 12–48 h until the 1950s when investigators at the same institution recommended prolonging the fast to 72 h in the asymptomatic patient (3). In the September 2000 issue of JCEM, Hirshberg et al. (4) question the necessity for extending the period of fasting beyond 48 h in patients being evaluated for a hypoglycemic disorder. They have confirmed previous reports that most persons with insulinoma have a positive fast within 48 h. The Mayo Clinic experience of positive fasts within 48 h in large series of patients with insulinoma has been reported as: 94% (n = 108, 1927–1965) (5) and 92% (n = 51, 1964–1975) (6). In the subsequent period, 1976 to the present, we have histological confirmation in 205 patients operated on for insulinoma. Among these, 170 underwent prolonged fasts according to a standard protocol. The fast was terminated within 12 h in 33%, 24 h in 65%, 36 h in 84%, 48 h in 93%, and 72 h in 99%. Two patients had negative fasts at 72 h; in one the fast remained negative through 96 h. Although a very rare event, negative 72-h fasts in insulinoma patients have been observed by others. Could any of these prolonged fasts have been terminated earlier without sacrificing diagnostic accuracy, as suggested by Hirshberg et al. (4)? The answer to this question is predicated partly on the purpose for which the prolonged fast is conducted. When the prolonged fast is done to determine the role of β-cell polypeptides in the genesis of previously documented hypoglycemia, the fast may be terminated when the plasma glucose is 55 mg/dL or less (7) because β-cell polypeptide levels are suppressed below that glucose level. Assuming that plasma glucose is being monitored on a frequent basis, there is no good reason for a fast done for that reason to be unduly prolonged. However, recognition of this purpose for the prolonged fast is relatively new (7). The classic end point of the prolonged fast has been the demonstration of Whipple’s triad. The latter requires knowledge of the current plasma glucose concentration and identification of concurrent neuroglycopenic symptoms. The decision to end a prolonged fast requires considerable judgement by the physician in attendance and is not amenable to retrospective review, except in the rare instances of egregious inattentiveness by the responsible physician. Could the prolonged fast be arbitrarily terminated at 48 h in the asymptomatic patient and an interpretation made later based on the plasma glucose and insulin concentrations, as suggested by the NIH investigators? To do so would preclude demonstration of Whipple’s triad, an important factor in the diagnosis of a hypoglycemic disorder. In addition, although a low plasma glucose is necessary, it is not sufficient to make a diagnosis of a hypoglycemic disorder because of the overlap between normal and hypoglycemic patients (7). Furthermore, even with the use of carefully generated criteria for hyperinsulinism, plasma insulin levels fall below the criterion for hyperinsulinemia in a small number of insulinoma patients in our experience and that of the NIH group. Although the criteria for hyperinsulinemia were generated from the 72-h fast (7, 8) and apply when the plasma glucose is low regardless of the duration of food deprivation the obverse, the demonstration of β-cell suppression in the nonhypoglycemic patient probably requires 72 h of fasting to generate conditions conducive to complete β-cell suppression. It is not known whether current criteria would apply at 48 h of fasting. Since an accurate diagnosis is so important because of implications for radiologic studies (some of which may be invasive) and major surgery, we take the position of conducting evaluations with great care and measuring not only all three β-cell polypeptides (insulin, C-peptide, and proinsulin) but also insulin surrogates such as β-hydroxybutyrate and plasma glucose response to iv glucagon. We are pleased that the NIH has followed our lead in measuring plasma proinsulin directly. However, due to limitations in their analysis, which failed to relate the proinsulin concentrations to glucose concentrations in insulinoma patients vs. controls, a diagnostic criterion could not be generated by them. Recommendations regarding optimal duration of the prolonged fast based solely on experience with insulinoma fails to take into consideration that when a prolonged fast is undertaken in a patient suspected to have a hypoglycemic disorder the presence of and, indeed, the nature of that disorder is not known. For instance, in recent years we have subjected noninsulinoma hypoglycemic patients to the prolonged fast who subsequently had the following diagnoses: ins
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An occasional patient with an insulinoma may not fulfill these criteria even during a 72-h fast (15,60), and a few have plasma insulin levels below 3 U/ml (18 pmol/liter) during fasting hypoglycemia, but plasma C-peptide levels are usually 0.6 ng/ml (0.2 mmol/liter) or greater and plasma proinsulin levels are usually 5.0 pmol/liter or greater in the latter patients.”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [60]
In the citing paper
“Most, but not all (60), patients with an insulinoma fulfill these diagnostic criteria in less than 72 h.”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [60]
In the citing paper
“Indeed, that occurs in less than 24 h in about two thirds, and in less than 48 h in the vast majority, of affected patients (60).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [60]
In the citing paper
“Of note, it is helpful to know that 95% of patients with insulinoma meet end-of-fast criteria by 48 h, but the fast may be extended to 72 h as 7% of patients with proven insulinomas developed hypoglycemia after 48 h [87,88].”
From Non-Diabetic Hypoglycemia: Evaluation and Management in Adults (2025) · cites this paper as [88]
Citations
Cites
CARCINOMA OF THE ISLANDS OF THE PANCREAS: HYPERINSULINISM AND HYPOGLYCEMIA
WILDER, R. M., ALLAN, F. N., POWER, M. H., & ROBERTSON, H. E. (1927) · Journal of the American Medical Association · doi:10.1001/jama.1927.02690050014007 · Cited by 443
HYPERINSULINISM AND DYSINSULINISM
HARRIS, S. (1924) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1924.02660100003002 · Cited by 326
Service, F. J., Dale, A. J. D., Elveback, L. R., & JIANG, N.-S. (1976) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(25)07100-9 · Cited by 288
Self-citationForty-Eight-Hour Fast: The Diagnostic Test for Insulinoma
Hirshberg, B., Livi, A., Bartlett, D. L., Libutti, S. K., Alexander, H. R., Doppman, J. L., Skarulis, M. C., & Gorden, P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6807 · Cited by 256
(1976) · PubMed · Cited by 244
Laroche, G. P. (1968) · Archives of Surgery · doi:10.1001/archsurg.1968.01330230071009 · Cited by 77
Cited by
Items 101–172 of 172
Kos‐Kudła, B., Bolanowski, M., Hubalewska–Dydejczyk, A., Krzakowski, M. J., Marek, B., Nasierowska-Guttmejer, A. M., Lampe, P., & Sworczak, K. (2008) · PubMed · Cited by 4
Kim, C. J., McKenzie, D., Joseph, J., Aytaman, Y. S., Lam, M. L., Soni, L., & McFarlane, S. I. (2019) · American Journal of Medical Case Reports · doi:10.12691/ajmcr-7-7-2 · Cited by 4
“However, in more recent work, Service et al have noted that a series of 205 patients with insulinoma, 14% of patients did not develop symptoms until after 48 hours of fasting, bringing into question the generalizability of the 48-hour fasting period as a diagnostic tool [3].”
MethodAdelmeyer, J., Schauer, C. M., & Kann, P. H. (2024) · Hormones · doi:10.1007/s42000-024-00542-1 · Cited by 4
“Perhaps the 72-hour fast is not sensitive enough and insulinomas are missed despite all the care taken [31 ].”
Malignant insulinoma in a patient with hypoglycemia
Wang, T., Vu, A., Mereu, L., & Ghosh, M. (2022) · Canadian Medical Association Journal · doi:10.1503/cmaj.211002 · Cited by 5
Popescu, A. D., Ciocâlteu, A., Gheonea, D. I., Iordache, S., Popescu, C. F., Săftoiu, A., & Ciurea, T. (2012) · PubMed Central · Cited by 4
Ketogenic Weight Loss Diet Rapidly Unmasks an Insulinoma
Meier, E., Winnicka, L., Lau, M., Vo, D., Joutovsky, A., & Shenoy, M. A. (2019) · Case Reports in Endocrinology · doi:10.1155/2019/9674245 · Cited by 3
A case report on a protracted course of a hidden insulinoma
Shah, F. Z. M., Mohamad, A. F., Zainordin, N. A., Warman, N. ‘. E., Hatta, S. F. W. M., & Ghani, R. A. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.102240 · Cited by 3
“Although the optimal duration has been debated, and traditionally taken as a 72-h fast, patients with insulinoma generally tend to develop hypoglycemia much sooner [5].”
BackgroundInsulinoma and other Hypoglycemias
Rushakoff, R. J., SIPERSTEIN, A. E., & Clark, O. H. (2009) · Cited by 3
[Clinical experience in 37 cases of insulinoma].
Díaz, A. G., Lucas, S. P., Ferraina, P. A., Ferraro, A., Puchulu, F., de Lima, A. P., Maselli, M. D. C., Gomez, R. M., & Bruno, O. D. (2006) · PubMed · Cited by 3
Insulinoma: Literature’s Review (Part 1)
AlJadir, S. J. (2015) · Endocrinology&Metabolism International Journal · doi:10.15406/emij.2015.02.00025 · Cited by 4
“In 2009 the Endocrine Society’s clinical practice guidelines for management of hypoglycemic disorders, had stated that the new cut-off of insulin for the diagnosis of insulinoma should be lowered to 3μU/mL in presence of hypoglycemia (serum glucose 55 mg/dL or less) [77,83-87].”
Background67-Year-Old Woman With Recurrent Hypoglycemia
MCDERMOTT, J. H., Kent, P. D., & Service, F. J. (2001) · Mayo Clinic Proceedings · doi:10.4065/76.9.939 · Cited by 3
Self-citationSu, L., Ma, X., Zhang, X., Yan, T., Zhong, X., Mai, J., Gong, Y., Li, J., & Xiao, H. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.01.015 · Cited by 2
“Supervised tests such as a 72-hour fast remains the gold standard, 12 however, it should be performed as an in-patient on an endocrine ward, increasing the cost of diagnosis.”
A Rare Case of Insulinoma in a Thin, Lean Adult Male: A Case Report
Khan, A. R., Wazir, M. H., Waqar, S., Ullah, R., & Gul, A. (2022) · Cureus · doi:10.7759/cureus.23414 · Cited by 2
“Up to 99% of insulinomas can be differentiated with the mentioned fasting test [3].”
BackgroundHypoglycemic disorders in adults
Dhanasekaran, M., & Vella, A. V. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00004-8 · Cited by 2
Insulinoma: an Evaluation by a Single Institution
Karakoç, D., Özdemir, A., & Sayek, İ. (2008) · Acta chirurgica Belgica · doi:10.1080/00015458.2008.11680287 · Cited by 2
“During the fasting period 33% of the patients become hypoglycaemic within 12 hours ; 65% of them become hypoglycaemic within 24 hours and 84% of the patients with insulinoma become hypoglycaemic within 36 hours (10).”
BackgroundInsulinoma. Criterios diagnósticos y tratamiento
Felechosa, M. D., Fernández, M. R., & Torre, E. L. M. (2009) · Avances en Diabetología · Cited by 2
Endocrine tumors of the pancreas
Moo‐Young, T. A., & Prinz, R. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1454-8.00061-8 · Cited by 2
A case of low serum insulin levels in a patient with insulinoma
Lo, C., & Sun, D. (2016) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-16-0041 · Cited by 2
Clinical Management of Insulinomas: A Single Institution’s Experience
Gül, Ö. Ö., Akkurt, A., Cander, S., Uğraş, N., Yerci, Ö., & Ertürk, E. (2014) · Endocrinology research and practice. · doi:10.4274/tjem.2613 · Cited by 2
Insulinoma and Chronic Kidney Disease: An Uncommon Conundrum Not to Be Overlooked
Foppiani, L., Panarello, S., Filauro, M., Scirocco, M. C., Cappato, S., Parodi, A. F., Sola, S., & Antonucci, G. (2017) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551417742620 · Cited by 2
Diagnosi e terapia dei disturbi ipoglicemici
Gullo, D., & Arpi, M. L. (2003) · L Endocrinologo · doi:10.1007/bf03344473 · Cited by 2
Insulinoma pancreático: casuística de um hospital central e revisão da literatura
Caldas, A. R., Teixeira, S., Giestas, A., Amaral, C., & Cardoso, M. H. (2015) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.1016/j.rpedm.2015.06.002 · Cited by 6
Hypoglycemia – An Enigmatic Dilemma
Gill, R. S. (2005) · Southern Medical Journal · doi:10.1097/01.smj.0000168132.71018.b3 · Cited by 2
“Most of the patients with insulinoma (65%) become hypoglycemic within the first 24 hours.(5) Should the patients become symptomatic, or to prevent them from becoming hypoglycemic at the end of the fast, 1 mg of glucagon should be administered IV.”
BackgroundHofland, J., & de Herder, W. W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00061-3 · Cited by 2
Insulinoma; a diagnostic challenge: a case report
Rafaey, W., Alvi, A. M., Aslam, S., Siddiqui, A. I., & Shafiq, W. (2024) · Journal of the Pakistan Medical Association · doi:10.47391/jpma.11001 · Cited by 1
Lundholm, M. D., Copley, D. J., Makin, V., & Rao, P. P. R. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.04.015 · Cited by 1
Nesidioblastosis in Patients With Severe Postbariatric Hypoglycemia: A Monocentric Case Series
Dawes, D., Trivedi, P. S., & Lawler, H. M. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf125 · Cited by 1
“A 72-hour fast has a sensitivity approaching 100% for insulinoma [28].”
Huabbangyang, T., Jiujinda, T., Kotwieng, T., Soithong, T., Nanthakun, A., & Rojsaengroeng, R. (2026) · Scientific Reports · doi:10.1038/s41598-026-39757-0 · Cited by 1
Pancreatic Neuroendocrine Tumors
Tsolakis, A. V., & Kanakis, G. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_50-2 · Cited by 1
Tõke, J., Czirják, G., Tóth, M., Rácz, K., & Patócs, A. (2014) · Orvosi Hetilap · doi:10.1556/oh.2014.30035 · Cited by 2
Extended metabolic evaluation of suspected symptomatic hypoglycemia: the prolonged fast and beyond
Soeters, M. R., Huidekoper, H. H., Durán, M., Ackermans, M. T., Endert, E., Fliers, E., Wijburg, F. A., Wanders, R. J. A., Sauerwein, H. P., & Serlie, M. J. M. (2010) · Metabolism · doi:10.1016/j.metabol.2010.01.024 · Cited by 1
“The prolonged fast is a well-validated clinical test to diagnose and explore spontaneous hypoglycemia [2].”
BackgroundInfluentialNeuroendokrine Tumoren des Gastrointestinaltraktes: Klinik und Diagnostik
Plöckinger, U. (2010) · Viszeralmedizin · doi:10.1159/000322359 · Cited by 1
Neuroendocrine Tumors of the Pancreas
Younan, G. J., Tsai, S., Evans, D. B., & Christians, K. K. (2016) · Springer eBooks · doi:10.1007/978-3-319-28089-9_7 · Cited by 1
Cryer, P. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00034-4 · Cited by 5
Insulinoma in the elderly : a report of three cases and review literature
Bernaerts, K., Gers, L., Verhaegen, A. A., Block, C. E. M. D., & Gaal, L. V. (2014) · JSM Clinical Case Reports · Cited by 2
Tumour-induced hypoglycaemia: a narrative review
Barber, T. M., Bannon, C. A. M., Weickert, M. O., Kyrou, I., & Randeva, H. S. (2021) · Journal of Laboratory and Precision Medicine · doi:10.21037/jlpm-20-110 · Cited by 1
“However, even with this approach, many patients will subsequently require hospital admission (33).”
BackgroundInfluentialLesson of the month: Recurrent falls and hypoglycaemia in an older woman
Ong, A. S., Wang, L. Q., & Aw, J. (2022) · Clinical Medicine · doi:10.7861/clinmed.2021-0671 · Cited by 1
Insulinome malin chez un patient en hypoglycémie
Wang, T., Vu, A., Mereu, L., & Ghosh, M. (2022) · Canadian Medical Association Journal · doi:10.1503/cmaj.211002-f · Cited by 2
Insulinoma in Patient With Nonalcoholic Steatohepatitis
Cain, D., Anguiano-Albarran, R., Obi, F., Pradeep, S., Mudrovich, S. A., & Simien, M. (2023) · Cureus · doi:10.7759/cureus.43469 · Cited by 1
“Insulin, proinsulin, C-peptide levels, and plasma glucose during a 72-hour fast have been found to have 99% sensitivity [9].”
BackgroundGupta, S., Goyal, A., Kandasamy, D., Agarwal, S., Damle, N., Pal, S., Tandon, N., & Jyotsna, V. P. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_87_24 · Cited by 1
“[12] For preoperative localization of insulinoma, contrast‑enhanced multiphase CT and IOUS were the most common modalities employed, and similar to our previous study, [2] IOUS and IOP demonstrated high sensitivity for localization of insulinoma.”
MethodKern, W. (2010) · Elsevier eBooks · doi:10.1016/b978-3-437-24680-7.10066-2
Pancreatogenous Hypoglycemic Syndrome - Insulinoma or Non-Insulinoma Origin (NIPHS)
Lee, C., Ging-Shing, J., & Tseng, H. (2011) · InTech eBooks · doi:10.5772/20973
“…standard for the diagnosis of insulinoma as the test enables the clinical demonstration of Whipple’s triad: symptoms and signs consistent with hypoglycemia, a concomitant plasma glucose level of 45 mg/dl or less, and reversibility of symptoms with administration of glucose (Service & Natt 2000).”
BackgroundLigand-Directed AAVP to Deliver a Therapeutic Transgene to Neuroendocrine Tumors of the Pancreas
Smith, T. L. (2013) · Digital Commons-TMC (Texas Medical Center)
López, J. M. G. (2004) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(04)70156-3
Protocolo diagnóstico de la hipoglucemia
López, J. M. G. (2004) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(04)70160-5
Demencia curada con cirugía: a propósito de un caso
Pérez, C. T., & García, J. Á. F. (2014) · Medicina Clínica · doi:10.1016/j.medcli.2014.02.012
Dementia solved with surgery: Report of a case
Pérez, C. T., & García, J. Á. F. (2015) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2014.02.003
Vezzosi, D., Bennet, A., Grunenwald, S., & Caron, P. J. (2016) · La Presse Médicale · doi:10.1016/j.lpm.2016.04.009
A Case of Insulinoma With Provoked Seizures for the Past Fourteen Years: A Case Report
kadkhodazadeh, H., Kazempour, M., & Salevatipour, B. (2015) · Archives of Critical Care Medicine · doi:10.17795/accm-7511
“Long-term survival is the rule after successful surgical removal of an insulinoma (2).”
BackgroundUeda, K., Lee, L., & Ito, T. (2018) · Wiley eBooks · doi:10.1002/9781119188421.ch133 · Cited by 1
Pršo, M., Szökeová, A., Havlíčeková, Z., Michnová, Z., Raffajová, D., Jancinová, M., Bánovčin, P., Bánovčin, P., Uhrík, P., & Hyrdel, R. (2018) · Pediatrie pro praxi · doi:10.36290/ped.2018.023
“U dospelých s neuroglykopenickými príznakmi a s hypolykémiou je potrebné realizovať biochemické vyšetrenie plazmatickej glukózy, C-peptidu, inzulinémie a proinzulínu počas 72 hodín trvajúceho hladového testu (7).”
Treatment of NET-Related Symptoms
Grimaldi, F., Vescini, F., & Kara, E. (2021) · Springer eBooks · doi:10.1007/978-3-030-72830-4_7
Mak, I. Y. F., & Grossman, A. B. (2022) · doi:10.1093/med/9780198870197.003.0112 · Cited by 1
Pancreatic Neuroendocrine Tumors
Tsolakis, A. V., & Kanakis, G. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_50
Grozinsky‐Glasberg, S., Reissman, P., & Gross, D. J. (2015) · Springer eBooks · doi:10.1007/978-3-662-45215-8_12
Lee, J. S., & Inabnet, W. B. (2015) · Springer eBooks · doi:10.1007/978-3-319-13662-2_42 · Cited by 1
Zandee, W. T., & de Herder, W. W. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65228-5 · Cited by 1
Benmayouf, T., Villoing, B., & Doumenc, B. (2019) · EMC - Urgenze · doi:10.1016/s1286-9341(19)42035-8
Das, P. K., & Islam, F. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815079364123010014
Postprandiale periode en vasten
Soeters, M. R. (2023) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-2868-0_12
Pancreatic Neuroendocrine Neoplasms. V-1. Epidemiology and Clinical Features
Chun, H. J., Park, S. J., Lim, Y. J., & Song, S. Y. (2023) · Springer eBooks · doi:10.1007/978-981-99-0815-8_64
Ueda, K., Fujimori, N., Jensen, R. T., & Ito, T. (2023) · Wiley eBooks · doi:10.1002/9781119876007.ch112
Othmane, E., & Fahoume, M. (2024) · Research Square · doi:10.21203/rs.3.rs-4066118/v1
Spontaneous hypoglycemia: A narrative review
Rahman, M. A., Islam, M. H., Khan, M. A., & Fariduddin, M. (2024) · Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh · doi:10.3329/jacedb.v3i2.78644
Unexplained Hypoglycemia in a Diabetic Patient Unveiling Insulinoma: A Case Report
Moinuddin, M. F. R., Sakarwala, A. S., Shahzad, N. U. A., & Ahmad, W. (2025) · INNOVAPATH · doi:10.63501/7xvwd239 · Cited by 1
Bilici, M. E., & Üstündağ, Y. (2025) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2025-0322
Strużek, K., Kwiatkowska, A., Mączka, E., Tracz, W., Świercz, P., Teper, K., Khiralla-Gawlik, S., Strzelecka, A. A., & Basak, A. E. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3659
“[40 ] Endogenous hypoglycemia caused by insulinoma was historically diagnosed based on abnormal levels of insulin and C-peptide, and more recently, proinsulin during fasting-induced hypoglycemia.”
Yu, M., Ji, X., & Zheng, P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1802157
“In some cases, the 72-hour test is recommended to reduce the risk of false-negatives results (21).”
Ito, M., Ishisaka, E., Kashii, Y., Goto, Y., Yoshio, Y., Sakai, W., Kameyama, T., Sasahara, M., Norose, T., & Ohike, N. (2026) · Internal Medicine · doi:10.2169/internalmedicine.7605-26
Öztürk, Y. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.10.002
Yu, J., Liu, Y., Lyu, L., Zhao, Y., Qi, M., Ping, F., Xu, L., Li, W., Xu, Q., Zhang, H., et al. (2022) · doi:10.3389/fendo.2022.994707.s001
Diagnosis and Localisation of Insulinoma
Sandeman, D. (2004) · Springer eBooks · doi:10.1007/978-1-85233-904-3_3
Metadata
- Authors
- Service, F. J., & Natt, N.
- Affiliations
- Mayo Clinic (US)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2000-11
- Volume
- 85
- Issue
- 11
- Pages
- 3973-3974
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1991309249
- Semantic Scholar
- 1f5c44abd64ff3b333eb7256b86405b956dc9f82
- Cited by
- 168
- References
- 5
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 8 · 2023: 10 · 2022: 12 · 2021: 5 · 2020: 4 · 2019: 6 · 2018: 7 · 2017: 10 · 2016: 6 · 2015: 10 · 2014: 10 · 2013: 5 · 2012: 9
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- insulinoma, prolonged fasting, hypoglycemia, diagnostic accuracy, fasting duration, plasma glucose, Mayo Clinic history
- MeSH terms
- Blood Glucose, Diagnosis, Differential, Fasting, Humans, Hyperinsulinism, Hypoglycemia, Insulinoma, Pancreatic Neoplasms, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.